Ignite Creation Date:
2025-12-24 @ 12:21 PM
Ignite Modification Date:
2026-01-27 @ 9:17 PM
Study NCT ID:
NCT00118261
Status:
COMPLETED
Last Update Posted:
2012-09-03
First Post:
2005-07-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer
Sponsor:
Case Comprehensive Cancer Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
CASE2204
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | NIH | View |